Skip to content
CompletedPhase 1Results posted

KET-RO Plus RO DBT for Treatment Resistant Depression

NCT06138691 · KET-RO · Washington University School of Medicine

Closed to entry
Status
Not accepting participants
Phase 1
Phase
16
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD). In addition, this study will develop and utilize innovative methodological approaches to demonstrate the feasibility of precision medicine with this type of therapy.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Decrease in Depressive Symptoms

    Measured over Approximately 5 months

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Males and females aged 18-65 * Moderate to severe persistent depression \[treatment resistant depression - TRD\] (exhibiting 2+ unipolar major depression episodes (non-delusional) with prior treatment non-response to antidepressant or psychosocial treatment * Treatment-resistant depression: defined as unipolar major depressive disorder, non-delusional (diagnosed by SCID-5, Structured Clinical Interview for the DSM ) that persists despite ≥ 2 adequate antidepressant trials of different classes in the current episode; including at least one evidence-based second-line treatment in the current episode (including serotonin norepinephrine reuptake inhibitors, bupropion, tricyclics, monoamine oxidase inhibitors, or augmentation with an atypical antipsychotic, stimulant, bupropion, lithium, or Triiodothyroinine) higher proportion of OC (over controlled) words endorsed compared to UC (Under controlled) words on the Word Pairs Checklist * no current or past psychosis * English speaking * Able to attend in-person behavioral sessions and ketamine/therapy visits * Willingness to have RO DBT-A as only psychosocial treatment engaged in (medication treatment may continue-but see below for exclusion) Exclusion Criteria: * Outside age range * Significant neurological condition (i.e., seizure, stroke, severe head injury) or mental retardation (IQ\<70) * Current or recent substance use disorder, actively suicidal or homicidal (e.g., requires hospitalization) * Use of naltrexone, memantine or medication considered contraindicated with ketamine * Baseline systolic BP \> 150 systolic or 90 diastolic at evaluation. Participants who initially present with elevated blood pressure may be re-assessed; and if needed, referred to their healthcare provider for hypertension management * Taking more than 2 adequately-dosed oral antidepressants * Inability to understand, speak and read English sufficiently * Not be pregnant or at risk of becoming pregnant * Medical conditions or medication usage that in the judgement of the investigators puts the patient at unreasonable safety risk * First degree relative with a psychotic diagnosis involving hallucinations, delusions, or disorganized thinking and speech (e.g. schizophrenia, schizoaffective disorder, etc)

Where

1 study site

FacilityCityRegionCountry
Washington University School of MedicineSt LouisMissouriUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT06138691 on ClinicalTrials.gov →

Last updated in the registry 2026-03-30. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits